Characterization of the metastatic phenotype of a panel of established osteosarcoma cells

Oncotarget

Volumn 6, Issue 30, 2015, Pages 29469-29481

  Hong, Ellen S ^a   Burkett, Sandra S ^a   Morrow, James ^a   Lizardo, Michael M ^a   Osborne, Tanasa ^c   Li, Samuel Q ^b   Luu, Hue H ^d   Meltzer, Paul ^a   Khanna, Chand ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Osteosarcoma; PHLDA1 TDAG51; Tumor metastasis

Indexed keywords

MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN PHLDA1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE; PHLDA1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

143B CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DLM8 CELL LINE; DOWN REGULATION; DUNN CELL LINE; EZRIN GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; HOS CELL LINE; HOS MNNG CELL LINE; HU09 CELL LINE; HU09 H3 CELL LINE; HU09 M112 CELL LINE; HU09 M132 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; K12 CELL LINE; K7M2 CELL LINE; KARYOTYPE; KRIB CELL LINE; LM7 CELL LINE; LUNG METASTASIS; METASTASIS POTENTIAL; MG63 2 CELL LINE; MG63 3 CELL LINE; MG63 CELL LINE; MOUSE; NONHUMAN; OSTEOSARCOMA CELL LINE; PHENOTYPE; SAOS CELL LINE; TE85 CELL LINE; TUMOR GENE; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; C3H MOUSE; CELL MOTION; COMPARATIVE STUDY; DISEASE COURSE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METABOLISM; OSTEOSARCOMA; PATHOLOGY; RNA INTERFERENCE; SECONDARY; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NEOPLASM INVASIVENESS; OSTEOSARCOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENOTYPE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945151363     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5177     Document Type: Article

References (61)

1. Sandberg AA and Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet. 2003; 145:1-30.
2. Marina N, Gebhardt M, Teot L and Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004; 9:422-441.
3. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y and Yamamuro T. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res. 1994; 54:3042-3048.
4. Chandar N, Billig B, McMaster J and Novak J. Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer. 1992; 65:208-214.
5. Benassi MS, Molendini L, Gamberi G, Ragazzini P, Sollazzo MR, Merli M, Asp J, Magagnoli G, Balladelli A, Bertoni F and Picci P. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. International journal of cancer Journal international du cancer. 1999; 84:489-493.
6. Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH and Huvos AG. Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol. 1993; 2:163-167.
7. Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus-Garcia R, Camargo OP, Pena W, Pericles P, Davi A, Prospero JD, Alves MT, Oliveira CR, Macedo CR, Mendes WL, Almeida MT, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 2006; 24:1161-1168.
8. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H and Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20:776-790.
9. Ottaviani G and Jaffe N. The etiology of osteosarcoma. Cancer Treat Res. 2009; 152:15-32.
10. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW and Taminiau AH. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007; 99:112-128.
11. Park CG, Lee SY, Kandala G, Lee SY and Choi Y. A novel gene product that couples TCR signaling to Fas(CD95) expression in activation-induced cell death. Immunity. 1996; 4:583-591.
12. Hossain GS, van Thienen JV, Werstuck GH, Zhou J, Sood SK, Dickhout JG, de Koning AB, Tang D, Wu D, Falk E, Poddar R, Jacobsen DW, Zhang K, Kaufman RJ and Austin RC. TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the cevelopment of atherosclerosis in hyperhomocysteinemia. J Biol Chem. 2003; 278:30317-30327.
13. Nagai MA, Fregnani JH, Netto MM, Brentani MM and Soares FA. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Res Treat. 2007; 106:49-56.
14. Toyoshima Y, Karas M, Yakar S, Dupont J, Lee H and LeRoith D. TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival. J Biol Chem. 2004; 279:25898-25904.
15. Park ES, Kim J, Ha TU, Choi JS, Soo Hong K and Rho J. TDAG51 deficiency promotes oxidative stress-induced apoptosis through the generation of reactive oxygen species in mouse embryonic fibroblasts. Exp Mol Med. 2013; 45:e35.
16. Sakthianandeswaren A, Christie M, D'Andreti C, Tsui C, Jorissen RN, Li S, Fleming NI, Gibbs P, Lipton L, Malaterre J, Ramsay RG, Phesse TJ, Ernst M, Jeffery RE, Poulsom R, Leedham SJ, et al. PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis. Cancer Res. 2011; 71:3709-3719.
17. Chiu ST, Hsieh FJ, Chen SW, Chen CL, Shu HF and Li H. Clinicopathologic correlation of up-regulated genes identified using cDNA microarray and real-time reverse transcription-PCR in human colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14:437-443.
18. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M and Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis. 2000; 18:261-271.
19. Haydon RC, Luu HH and He TC. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res. 2007; 454:237-246.
20. Bjornland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O and Maelandsmo GM. Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res. 2005; 127:151-156.
21. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004; 10:182-186.
22. Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, Araujo DM, Chen K and Zhang W. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer. 117:4925-4938.
23. Kashima T, Nakamura K, Kawaguchi J, Takanashi M, Ishida T, Aburatani H, Kudo A, Fukayama M and Grigoriadis AE. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. International journal of cancer Journal international du cancer. 2003; 104:147-154.
24. Luu HH, Zhou L, Haydon RC, Deyrup AT, Montag AG, Huo D, Heck R, Heizmann CW, Peabody TD, Simon MA and He TC. Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett. 2005; 229:135-148.
25. Wang Y, Yang X, Yamagata S, Yamagata T and Sato T. Involvement of Ext1 and heparanase in migration of mouse FBJ osteosarcoma cells. Mol Cell Biochem. 2013; 373:63-72.
26. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, Hewitt S, Triche T, Meltzer P and Khanna C. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC genomics. 2009; 10:625.
27. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC and Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 2004; :286-291.
28. Stiller CA, Craft AW and Corazziari I. Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study. Eur J Cancer. 2001; 37:760-766.
29. Hay RJ. Methods for authenticating cell lines. Dev Biol Stand. 1992; 76:25-37.
30. Ek ET, Dass CR and Choong PF. Commonly used mouse models of osteosarcoma. Crit Rev Oncol Hematol. 2006; 60:1-8.
31. Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PC, Llombart-Bosch A and Cleton-Jansen AM. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest. 2011; 91:1195-1205.
32. Dass CR, Ek ET and Choong PF. Human xenograft osteosarcoma models with spontaneous metastasis in mice: clinical relevance and applicability for drug testing. J Cancer Res Clin Oncol. 2007; 133:193-198.
33. Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, Yin H, Montag AG, Simon MA, Peabody TD, Haydon RC, Rinker-Schaeffer CW and He TC. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis. 2005; 22:319-329.
34. Xie X, Brunner N, Jensen G, Albrectsen J, Gotthardsen B and Rygaard J. Comparative studies between nude and scid mice on the growth and metastatic behavior of xenografted human tumors. Clin Exp Metastasis. 1992; 10:201-210.
35. Hayashida N, Inouye S, Fujimoto M, Tanaka Y, Izu H, Takaki E, Ichikawa H, Rho J and Nakai A. A novel HSF1-mediated death pathway that is suppressed by heat shock proteins. EMBO J. 2006; 25:4773-4783.
36. Oberst MD, Beberman SJ, Zhao L, Yin JJ, Ward Y and Kelly K. TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation. BMC Cancer. 2008; 8:189.
37. Muff R, Ram Kumar RM, Botter SM, Born W and Fuchs B. Genes regulated in metastatic osteosarcoma: evaluation by microarray analysis in four human and two mouse cell line systems. Sarcoma. 2012; 2012:937506.
38. Huang Y, Dai H and Guo QN. TSSC3 overexpression reduces stemness and induces apoptosis of osteosarcoma tumor-initiating cells. Apoptosis. 2012; 17:749-761.
39. Yu Y, Luk F, Yang JL and Walsh WR. Ras/Raf/MEK/ERK pathway is associated with lung metastasis of osteosarcoma in an orthotopic mouse model. Anticancer Res. 2011; 31:1147-1152.
40. Sasaki K, Hitora T, Nakamura O, Kono R and Yamamoto T. The role of MAPK pathway in bone and soft tissue tumors. Anticancer Res. 2011; 31:549-553.
41. Noh K, Kim KO, Patel NR, Staples JR, Minematsu H, Nair K and Lee FY. Targeting inflammatory kinase as an adjuvant treatment for osteosarcomas. J Bone Joint Surg Am. 2011; 93:723-732.
42. Werner S, Mendoza A, Hilger RA, Erlacher M, Reichardt W, Lissat A, Konanz C, Uhl M, Niemeyer CM, Khanna C and Kontny U. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma. Cancer Chemother Pharmacol. 2008; 62:19-31.
43. Mendoza A, Gharpure R, Dennis J, Webster JD, Smedley J and Khanna C. A novel noninvasive method for evaluating experimental lung metastasis in mice. J Am Assoc Lab Anim Sci. 2013; 52:584-589.
44. Ren L, Hong SH, Cassavaugh J, Osborne T, Chou AJ, Kim SY, Gorlick R, Hewitt SM and Khanna C. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene. 2009; 28:792-802.
45. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. 1995; Series B 57:289-300.
46. Mendoza A, Hong SH, Osborne T, Khan MA, Campbell K, Briggs J, Eleswarapu A, Buquo L, Ren L, Hewitt SM, Dakir el H, Garfield S, Walker R, Merlino G, Green JE, Hunter KW, et al. Modeling metastasis biology and therapy in real time in the mouse lung. The Journal of clinical investigation. 2010; 120:2979-2988.
47. Trapnell C, Pachter L and Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009; 25:1105-1111.
48. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ and Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nature biotechnology. 2010; 28:511-515.
49. Ramskold D, Wang ET, Burge CB and Sandberg R. An abundance of ubiquitously expressed genes revealed by tissue transcriptome sequence data. PLoS computational biology. 2009; 5:e1000598.
50. McAllister RM, Gardner MB, Greene AE, Bradt C, Nichols WW and Landing BH. Cultivation in vitro of cells derived from a human osteosarcoma. Cancer. 1971; 27:397-402.
51. Rhim JS, Putman DL, Arnstein P, Huebner RJ and McAllister RM. Characterization of human cells transformed in vitro by N-methyl-N'-nitro-Nnitrosoguanidine. International journal of cancer Journal international du cancer. 1977; 19:505-510.
52. Hensler PJ, Annab LA, Barrett JC and Pereira-Smith OM. A gene involved in control of human cellular senescence on human chromosome 1q. Molecular and cellular biology. 1994; 14:2291-2297.
53. Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D and Woods VL, Jr. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res. 1993; 53:4890-4895.
54. Jia SF, Worth LL and Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis. 1999; 17:501-506.
55. Billiau A, Edy VG, Heremans H, Van Damme J, Desmyter J, Georgiades JA and De Somer P. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother. 1977; 12:11-15.
56. Su Y, Luo X, He BC, Wang Y, Chen L, Zuo GW, Liu B, Bi Y, Huang J, Zhu GH, He Y, Kang Q, Luo J, Shen J, Chen J, Jin X, et al. Establishment and characterization of a new highly metastatic human osteosarcoma cell line. Clin Exp Metastasis. 2009; 26:599-610.
57. Kawai A, Ozaki T, Ikeda S, Oda T, Miyazaki M, Sato J, Taketa K and Inoue H. Two distinct cell lines derived from a human osteosarcoma. J Cancer Res Clin Oncol. 1989; 115:531-536.
58. Kimura K, Nakano T, Park YB, Tani M, Tsuda H, Beppu Y, Moriya H and Yokota J. Establishment of human osteosarcoma cell lines with high metastatic potential to lungs and their utilities for therapeutic studies on metastatic osteosarcoma. Clin Exp Metastasis. 2002; 19:477-485.
59. Nakano T, Tani M, Ishibashi Y, Kimura K, Park YB, Imaizumi N, Tsuda H, Aoyagi K, Sasaki H, Ohwada S and Yokota J. Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis. 2003; 20:665-674.
60. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S and Yoshikawa H. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. International journal of cancer Journal international du cancer. 1998; 76:418-422.
61. Schmidt J, Strauss GP, Schon A, Luz A, Murray AB, Melchiori A, Aresu O and Erfle V. Establishment and characterization of osteogenic cell lines from a spontaneous murine osteosarcoma. Differentiation; research in biological diversity. 1988; 39:151-160.